

What is the Current Standard of Care in Treating PV?

Time	Question
01:09	What did we learn and how did Hydroxyurea become the initial standard of care in PV?
04:00	Regarding the decision for cytoreduction, who do you choose to use a reduction, and when you choose to use it? What are your goals of treatment?
06:54	What are possible side effects when you are looking at patient's blood counts?
09:40	Does Hydroxyurea lead to acute leukemia in these patients? Or is it a contributor in patients who end up progressing to acute leukemia?
12:46	What are the benefits we have seen with ruxolitinib in P. Vera and how that positions itself as second-line therapy for PV?
15:54	How frequently should we be checking blood counts on patients with P. Vera who are on ruxolitinib and patients with myelofibrosis? How else are we monitoring them for toxicities?
16:34	Are there unmet needs in the current line of the therapy? Are there unmet needs in P. Vera as well?